

Regio and diastereoselective synthesis of dispiroindole-3,2'-pyrrolidine/pyrrolizines /pyrrolidines-3',3''-indole derivatives through 1,3-dipolar addition and their in vitro activity studies against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant M. tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2)

¹Hari Krishnan.P.S.

¹Associate Professor

¹Department of Chemistry,

¹The Madura College, Madurai, India

harikimku@gmail.com

Abstract— An efficient synthesis of highly medicinally important dispiroindole-3,2'-pyrrolidine/pyrrolizines /pyrrolidines-3',3''-indole derivatives was achieved by the 1,3-dipolar cycloaddition of azomethine ylide generated in situ by the reaction between isatin and proline/L-Phenyl glycine / Sarcosine to (3-Z)-6-chloro-3-(benzylidene-5-(2-chloroethyl-1,3-dihydro-2H-indol-2-one. These dipolarophiles upon cycloaddition with azomethine ylides affords stereoselectively novel dispiroindole-3,2'-pyrrolidine/pyrrolizines /pyrrolidines-3',3''-indole derivatives in high yield, almost quantitatively. These compounds were characterized by IR, NMR spectroscopy. It is planned to screen these compounds for their in vitro activity against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant M. tuberculosis (MDR-TB) and Mycobacterium smegmatis (MC2) using agar dilution method.

Key words— 1,3-dipolar cycloaddition, azomethine ylide, pyrrolidine.

GENERAL ASPECTS OF DISPIROHETEROCYCLES AND THEIR IMPORTANCE

One of the goals of synthetic organic chemists is the clear stereo defined synthesis of highly complicated structures. Splendidly the very most important great task is the regio- and stereo controlled generation of spiro compounds. Bicyclic organic compounds, comprise rings connected through just one atom are known as Spiro compounds[1], have several unique characteristics, such as 3D structural properties, related to their inherent rigidity, notably, these compounds display a broad range of biological activities.

Nowadays, spiro compounds are attracting increasing attention as scaffolds in modern drug discovery. Spiro compounds are present in numerous number of natural products such as the angiotensin antagonist irbesartan [2] **1**, analgesic morphine [3] **2**, β -vetivone **3**, the antibiotic monensin **4**, (-)-acorenone [4] **5**, opioid receptor agonist oxycodone [5] **6**, Shizuka-acordienol **7**, rosmadial **8**, (-)-cannabispirenone A **9**, trigolute B **10** used in Thai medicine, marine alkaloid (+)-dicorhabdin A **11**, and alkaloid citrinalin A **12**.

Taking advantage of their rigidity and extremely precise 3D structure, spiro compounds have emerged as one of the most attractive ligand and catalyst motifs in asymmetric synthesis as well as catalysis. Mainly, these scaffolds are derived from Spinol **13** and show excellent stereochemical recognition. Some examples such as spiro(oxazoline) **14**, Spinol derived phosphoric acid **15** and the diphosphinespiro **P16** are illustrated in **Fig 1**





Fig.1 Examples of Compounds containing Spiro cyclic ring.

RESULTS & DISCUSSION

In the present investigation, 1,3 d dipolar cycloaddition of azomethineylide generated insitu by the reaction between isatin**18** and proline**19**/ L-Phenyl glycine**20**/ Sarcosine**21** to (3-Z)-6-chloro-3-(benzylidene-5-(2-chloroethyl-1,3-dihydro-2H-indol-2-one **17** results in highly regio and stereo selective formation of highly medicinally important dispirocompound **22**, **23** & **24** in good yield




Scheme-1

Initially, the reaction of 6-chloro-5-(2-chloroethyl)-1,3-dihydro-2H-indol-2-one with various aldehydes in the presence of Potassium carbonate using methanol as the solvent results in the monobenzylidene compound **17** in good yield. This undergoes 1,3-dipolar cycloaddition to give the diastereoisomers **22**, **23** & **24** in good yield (Table 1).

Table 1. Synthesis of diastereoisomers **22**, **23** & **24**

Entry	Comp.	Ar	Yield (%)		
			22	23	24
1	A	<i>p</i> -OCH ₃ C ₆ H ₄	92	88	85
2	B	C ₆ H ₅	82	85	86
3	C	<i>p</i> -CH ₃ C ₆ H ₄	95	93	92
4	D	<i>m</i> -BrC ₆ H ₄	78	80	85
5	E	<i>o</i> -ClC ₆ H ₄	82	75	98
6	F	<i>p</i> -BrC ₆ H ₄	84	85	94
7	G	<i>p</i> - <i>N,N</i> -DimethylC ₆ H ₄	86	88	96
8	H	<i>m</i> -NO ₂ C ₆ H ₄	82	95	95
9	I	<i>p</i> -NO ₂ C ₆ H ₄	88	94	86
10	J	<i>p</i> -ClC ₆ H ₄	92	98	88

Figure 2. Selected proton chemical shifts of **22a**

The structure of dispiro compound **22** was elucidated using ^1H , and ^{13}C NMR spectroscopic data as described for a representative example, **22a** (**Figure 2**). The ^1H NMR spectrum of **22a** has three diastereotopic protons present in the pyrrolidine ring (C-20, 21 & 22) appear as a doublet of doublet at 2.40;2.30 ppm, 1.64;1.54ppm and 1.66;1.41ppm respectively, with coupling constant $J = 7.1$ Hz and 7.0 Hz. The H-37 appear as a multiplet at 2.63 ppm. The C-13 proton appears at 3.45 ppm as a doublet with $J = 7$. Hz. A triplet at 2.71ppm is due to the $-\text{CH}_2$ protons and a triplet at 3.71 ppm is because of $-\text{CH}_2\text{Cl}$ protons. The $-\text{NH}$ protons at indoline and isatin ring present at 10.66 and 10.68 ppm respectively. The methoxy protons appears as a singlet at 3.81 ppm.




Figure 3. Selected ^{13}C chemical shifts of **22a**

^{13}C NMR spectroscopic data as described for a representative example, **22a** (**Figure 3**). The carbonyl carbons of indoline and isatin appears at 182.1 and 172.ppm. The chemical shift of spiro carbons C-13, C-8 and C-12 are 38.0, 63.3 and 67.3 ppm respectively. A peak at 55.5 ppm is due to methoxy carbon (C-39). The C-33 carbon ($-\text{CH}_2$) and C-34 carbon ($-\text{CH}_2\text{Cl}$) appears at 32.4 and 40.9 ppm.

ANTIMYCOBACTERIAL ACTIVITY OF DISPIROINDOLE-3,2'-PYRROLIDINE/PYRROLIZINES /PYRROLIDINES- 3',3''-INDOLE DERIVATIVES AGAINST *M. TUBERCULOSIS* H37Rv

All the compounds were subjected to High Throughput Screening (HTS) for in vitro antimycobacterial activity against *Mycobacterium tuberculosis* H37Rv using microdilution Alamar Blue (AB) broth assay reported by Collins and Franzblau. Five standard drugs were used as references along with the synthesized compounds for the assay. All the dispiro hybrid heterocycles, except **22c**, **22e**, **22j** and **22f**, showed $\text{IC}_{50} > 29.9$ μM (Table 2) viz. higher potency than the standard pyrimethamine ($\text{IC}_{50} = 37.35$ μM) and all the compounds, except **6f**, were more potent than pyrimethamine ($\text{IC}_{90} = 74.96$ μM). The IC_{50} values of nine compounds (**22a**, **22b**, **22h**, **22i**, **22b** and **22l**) are in the range of 1.07–11.07 μM indicating that they are more active than cycloserine ($\text{IC}_{50} = 12.47$ μM). Compound **23g**, having an IC_{50} value of 12.87 μM , are as potent as cycloserine. The IC_{90} values of four compounds (**22b** and **22h**) reveal that their activities are close to that of cycloserine. Compound **22h** with an IC_{50} value of 1.07 is more active than the standard ethambutol ($\text{IC}_{50} < 1.56$ μM). The IC_{90} values of fifteen compounds (**22a**, **22b**, **22d**, **22h**, **22i**, **23a**, **23b**, **23d**, **23g**, **23h**, **23j**), ranging from 1.98 μM to 27.86 μM , have higher activity than ethambutol ($\text{IC}_{90} = 32.79$ μM). The MIC values (Table 3. 2) of compounds **22h** and **22j** show better activity than the standard drugs like cycloserine, ethambutol and pyrimethamine. Compounds **46h** and **22i** possess potency equal to that of cycloserine and more potent than pyrimethamine. Compounds **22a–c**, **23g**, **23a–c**, **23e**, **23g–j**, **22l**, **22m** and **22n** show higher potency than pyrimethamine ($\text{MIC} = 100.00$ μM) and compounds **23e**, **23f**, **23j**, **23n**, **22d** and **22f** are found to be as potent as pyrimethamine. **22h** has emerged as the most active derivative with an IC_{50} value of 1.07 μM , being more potent than cycloserine about 12 times, pyrimethamine about 37 times and ethambutol. Similarly **23j** with $\text{IC}_{50} = 2.87$ μM is more active than both cycloserine about 4 times and pyrimethamine about 12 times.

Table 2. Antimycobacterial activity of dispiroindole-3,2'-pyrrolidine/pyrrolizines /pyrrolidines- 3',3''-indole derivatives against *M. tuberculosis* H37Rv

Entry	Compound	IC_{50} (μM)	IC_{90} (μM)	MIC (μM)	CY (lg/ml)	Compound	IC_{50} (μM)	IC_{90} (μM)	MIC (μM)	CYT (lg/ml)
1	22a	11.07	21.98	50.00	>6.25	23a	13.19	25.90	50.00	>6.25
2	22b	08.46	12.42	50.00	>6.25	23b	07.20	15.50	50.00	>6.25
3	22c	29.95	41.87	50.00	>6.25	23c	21.91	47.93	50.00	>6.25
4	22d	15.17	27.86	100	>6.25	23d	16.30	25.50	100.0	>6.25
5	22e	47.20	66.50	100.0	>6.25	23e	28.57	47.72	50.00	>6.25
6	22f	25.87	44.60	100.0	>6.25	23f	44.95	74.96	100.0	>6.25
7	22g	18.28	36.50	50.00	>6.25	23g	12.87	24.60	50.00	>6.25
8	22h	04.28	09.86	25.00	>6.25	23h	16.38	21.97	50.00	>6.25
9	22i	5.81	16.13	25.00	>6.25	23i	17.20	35.50	50.00	>6.25
10	22j	47.20	66.50	100.0	>6.25	23j	08.57	14.72	50.00	>6.25
Standard										
Amikacin							0.07	0.08	0.16	>6.25

Cycloserine							12.47	13.49	25.00	>6.25
Ethambutol							<1.56	32.79	12.50	>6.25
Isoniazid							0.18	0.29	0.31	>6.25

CONCLUSION

In the present investigation, 1,3 d dipolar cycloaddition of azomethineylide generated insitu by the reaction between isatin and proline to (3-Z)-6-chloro-3-(benzylidene-5-(2-chloroethyl-1,3-dihydro-2H-indol-2-one results in highly regio and stereo selective formation of highly medicinally important dispiro compound in good yield. The synthesized compounds were subjected to in vitro activity studies against Mycobacterium tuberculosis H37Rv (MTB), multi-drug resistant M. tuberculosis (MDR-TB) and Mycobacterium smegmatis(MC2). Many compounds shows considerable activity.

ACKNOWLEDGMENT

The author acknowledges the UGC for funding under the Major project (UGC letter No: 43-244(SR) and The Madura College Management for their constant support.

REFERENCES

- [1] R.RIOS. CHEM. SOC. REV. 2012 41, 1060-1074.
- [2] (a) J.F.M.da silva; S.J.Garden; A.C.J.Pinto. *Prazchem .soc* **2001**,12,273. (b) J.O.Ergman; U.Tilotam. *etrahedron***1988**,41,2879.
- [3] (a) L.Chiyoazu; E.Hanselt; J.GUT; P.J.Rosenthal; J.H.J.Mckerrowb: K.Chible. *.Bioorg.Med.chem.Lett***2003**,13, 3527.(b) M.R.Almeida; G.G.Leitas; Br.Silvar; J.P.Barbosa; A.J.Pinto. *Braz.chem.soc.***2010**,21,764
- [4] J.F.M.Da silva; S.J.Gorden; A.C.Pinto. *J.Braz.chemsoc* **2001**,12,273
- [5] J.F.M.DaSilva; S.J.Garden..*J. Braz. Chem. Soc.***2002**, 13, 275.